Origin Materials (ORGN) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
27 Mar, 2026Executive summary
Significant progress in PET cap commercialization, with new designs delivered to about thirty prospects and internal testing showing improved performance and industry benchmark compliance.
First PET caps reached store shelves in California in August 2025, marking a milestone for market acceptance.
Strategic focus shifted solely to caps and closures, ceasing investment in the Furanics platform and reducing headcount.
Strategic review ongoing, exploring financing, asset sales, technology licensing, and potential business combinations.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $53.5 million as of December 31, 2025.
Q4 2025 revenue was $3.0 million, down from $9.2 million year-over-year due to winding down the supply chain activation program.
Full year 2025 revenue was $18.9 million, down from $31.3 million in 2024.
Q4 net loss was $194.1 million, mainly due to a $165.9 million non-cash asset impairment.
Net accounts receivable at year-end was $13 million, expected to be collected as supply chain program winds down.
Outlook and guidance
Adjusted EBITDA run rate breakeven now projected for 2028, delayed from previous 2027 guidance due to extended customer qualification and gradual commercialization.
Existing cash expected to fund operations into Q3 2026, with urgent need for new financing or cost reductions.
Commercialization expected to proceed via multiple smaller launches rather than a single large rollout.
Latest events from Origin Materials
- Stockholders approved a reverse split and major share issuance, advancing strategic milestones.ORGN
EGM 202618 Feb 2026 - $100M+ PET cap deal signed; Q2 loss $19.5M; Q4 2024 production on track.ORGN
Q2 20241 Feb 2026 - Strong PET cap demand, $100M+ MOU, and EBITDA positivity targeted for 1H 2026.ORGN
Q3 202414 Jan 2026 - Rapid transformation to PET caps leverages technical strengths, innovation, and scalable growth.ORGN
Fireside Chat9 Jan 2026 - Key votes on reverse stock split and major share issuance set for February 2026.ORGN
Proxy Filing6 Jan 2026 - Approval sought for reverse split and convertible note share issuance to support listing and funding.ORGN
Proxy Filing6 Jan 2026 - Commercial PET cap production launched; 2026 revenue projected at $110M–$140M, EBITDA positive by year-end.ORGN
Q4 202426 Dec 2025 - Approval sought for reverse split and share issuance to support listing and financing.ORGN
Proxy Filing23 Dec 2025 - High demand and technical leadership drive confidence in growth and successful CapFormer deployment.ORGN
Investor Q&A19 Dec 2025